The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or ...
"The city has made significant progress in areas such as new energy vehicles and biopharmaceuticals. Additionally, as the ...
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved Tivdak for the treatment of advanced or recurrent ...
Japan accepted 2 Palestinians injured in the Gaza war for medical treatment Wednesday. It's the first time since the current ...
The Ministry’s recent announcement highlighted that, in the year 2024, the new HIV infections amounted to 664—a decrease of 5 cases compared to the previous year—while AIDS cases showed a concerning ...
(RTTNews) - Genmab A/S (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK for the treatment of advanced or recurrent cervical cancer that has progressed on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback